Results from neoadjuvant chemotherapy followed by surgery compared to chemoradiation for Stage IB2-IIB cervical cancer: EORTC55994

Greggi, Stefano; Kenter, Gemma G.; Vergote, Ignace; Katsaros, Dionyssios; Kobierski, Juliusz; Massuger, Lfag; Doorn, PA van; Landoni, Fabio; Velden, Jacob van de; Reed, Nicholas; Coens, Corneel; Luijk, Iske van; Ottevanger, Petronella B.; Colombo, Nicoletta; Herráez, A. Casado

doi:10.1136/ijgc-2019-esgo.13

Cited by 8 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…McConmark in 2013 [28] published encouraging results using neoadjuvant chemotherapy followed by concurrent chemoradiation in locally advanced disease with central bulky tumors [28], as well as other authors [29,30], arrived to similar conclusions, also considering the quality of life of these patients [31]. At this time, it is important to remember that was proven no difference between neoadjuvant chemotherapy vs. chemoradiation [32,33].…”

Section: Introductionmentioning

confidence: 77%

Prognostic significance of the Central Tumor Size (CTS) in Cervical Cancer (CC) stages IIb and IIIb: What should we do with the FIGO staging system and therapeutic strategies?

Soderini¹,

Aragona²,

Quintaie³

et al. 2021

Arch Cancer Sci Ther

View full text Add to dashboard Cite

Cervical cancer constitutes an issue in public health, becoming the leading cause of death by cancer in women between 20-40 years of age in Latin America. In Argentina 5000 new cases are diagnosed each year, where more than 56% are in advanced stages. The aim of the present current opinion or critical review article is to remark the importance of the prognostic significance of the Central Tumor Size in stages IIB and IIIB cervical cancer, as well as to propose a new FIGO Staging System for Cervical cancer and trying to find out a role for the different therapeutic strategies for those cases.

show abstract

Section: Introductionmentioning

confidence: 77%

Prognostic significance of the Central Tumor Size (CTS) in Cervical Cancer (CC) stages IIb and IIIb: What should we do with the FIGO staging system and therapeutic strategies?

Soderini¹,

Aragona²,

Quintaie³

et al. 2021

Arch Cancer Sci Ther

View full text Add to dashboard Cite

show abstract

“…The recent result of a large-scale clinical study for stage IB2-IIB cervical carcinoma demonstrated no difference in 5-year OS between NACT-RS and CCRT. Compared to CCRT, patients with stage IB2 trended for better results in NACT-RS [14]. A single-center, Phase III randomized controlled trial reported that CCRT resulted in superior DFS than ACR-RS in locally advanced cervical cancer.…”

Section: Discussionmentioning

confidence: 99%

Clinical outcome of FIGO 2018 stage IB3/IIA2 cervical cancer treated by neoadjuvant chemotherapy followed by radical surgery due to lack of radiotherapy equipment: A retrospective comparison with concurrent chemoradiotherapy

et al. 2022

View full text Add to dashboard Cite

This study aimed to assess neoadjuvant chemotherapy’s clinical outcomes such as efficacy, toxicity, and survival outcomes followed by radical hysterectomy ((NACT-RS) among women with cervical cancer stage IB3 and IIA2, by comparing concurrent chemoradiotherapy (CCRT) and NACT-RS. The study retrospectively reviewed patients with (2018 FIGO) stage IB3 and IIA2 cervical cancer who received preoperative neoadjuvant chemotherapy followed by NACT-RS or concurrent chemoradiotherapy (CCRT). The outcome measures were the 5-year survival and complication rates between the two groups. The median follow-up was 75 months. In total, 218 patients had stage IIA2, 136 patients had stage IB3, 201 patients received CCRT, and 153 patients received preoperative NACT-RS. In the CCRT group, the incidence of early complications (myelosuppression, gastrointestinal and urinary) was higher compared with that in the NACT-RS group (76.1 vs. 26.1%; p < 0.001, respectively). There was no significant difference between the two study groups concerning late complications. Five-year PFS was 79.9% and 85.5% in the NACT-RS and CCRT groups, respectively (p = 0.093). Five-year OS was 86.9% and 85.5% in the NACT-RS and CCRT groups, respectively (p = 0.97). In the multivariate clinicopathologic characteristics analysis for OS, initial tumor size > 4.3 cm (HR 5.11; p < 0.001), AC/ASC (HR 1.89; p = 0.02), histologic grade 2–3 (HR 2.25; p = 0.04), and 2018 FIGO stage IIA2 (HR 8.67; p < 0.001) were independent risk factors. The survival of patients with stage IB3 and IIA2 cervical cancer treated with NACT-RS was similar to that of patients treated with CCRT without increasing side effects.

show abstract

“…Preoperative HDR-VOBT with a dose of 8 Gy did not increase the incidence of surgical complications. The effect of preoperative brachytherapy on the survival of patients with locally advanced cervical cancer remains controversial, but most studies confirmed that it has no effect on the survival rate of patients with stages IB2 and IIA cervical cancer ( 20 , 21 ). Our study aimed to analyze the efficacy and safety of preoperative HDR-VOBT with a dose of 8 Gy to control vaginal bleeding in patients with early-stage cervical cancer.…”

Section: Discussionmentioning

confidence: 99%

Efficacy of preoperative brachytherapy for controlling vaginal bleeding in early-stage cervical cancer: a retrospective study

Ping¹,

Zeng²,

Sun³

et al. 2021

Transl Cancer Res TCR

View full text Add to dashboard Cite

Background: In our clinical study, 11% of the patients with early-stage cervical cancers had different degrees of vaginal bleeding, which required a preoperative intervention. We set to assess the efficacy and safety of preoperative high-dose rate vaginal ovoid brachytherapy (HDR-VOBT) for the treatment of vaginal bleeding in women with early cervical cancer.Methods: We retrospectively identified and reviewed patients with vaginal bleeding and early-stage cervical carcinoma, treated between January 2011 and December 2014 (median follow-up of 69 months).Of the 116 patients, 59 received preoperative HDR-VOBT (a dose of 8 Gy at 0.5 cm from the tumor surface), and 57 received traditional vaginal packing with gauze alone, followed by radical hysterectomy and lymphadenectomy. Analysis of the clinical parameters was performed using the chi-square test. The outcome measures were the 3-and 5-year survival and the complication rate.Results: From the 116 patients, 25 had stage IB1, 49 had stage IB2, and 42 had stage IIA1 cervical cancer.No differences were observed regarding the 5-year overall survival (OS) (91.5% vs. 91.2%) and diseasefree survival (DFS) (76.3% vs. 86%) between the preoperative HDR-VOBT group and the vaginal packing with gauze group. The mean volume of blood loss due to vaginal bleeding after treatment was 83.4 (range: 30-150) mL: 56.8 (range: 30-80) mL in the preoperative HDR-VOBT group and 111.1 (range: 80-150) mL in the gauze packing group (P<0.001). The mean time to achieve hemostasis was 3.5 h in the preoperative HDR-VOBT group and 8.1 h in the vaginal packing with gauze group (P<0.001). There was no significant difference in postoperative risk factors, complications, and survival between the two groups.

show abstract

Results from neoadjuvant chemotherapy followed by surgery compared to chemoradiation for Stage IB2-IIB cervical cancer: EORTC55994

Cited by 8 publications

References 0 publications

Prognostic significance of the Central Tumor Size (CTS) in Cervical Cancer (CC) stages IIb and IIIb: What should we do with the FIGO staging system and therapeutic strategies?

Prognostic significance of the Central Tumor Size (CTS) in Cervical Cancer (CC) stages IIb and IIIb: What should we do with the FIGO staging system and therapeutic strategies?

Clinical outcome of FIGO 2018 stage IB3/IIA2 cervical cancer treated by neoadjuvant chemotherapy followed by radical surgery due to lack of radiotherapy equipment: A retrospective comparison with concurrent chemoradiotherapy

Efficacy of preoperative brachytherapy for controlling vaginal bleeding in early-stage cervical cancer: a retrospective study

Contact Info

Product

Resources

About